What are the optimal temporal windows for TREM2 inhibition vs activation in Alzheimer's disease progression?

Novel Hypotheses: Temporal Switching Criteria for Biphasic TREM2 Modulation in AD

1. Metabolic State–Driven Switching Threshold

Description: Microglial metabolic reprogramming (Warburg-like glycolytic shift vs. oxidative phosphorylation) serves as the natural switch point for TREM2 direction. Early amyloid response requires TREM2-mediated oxidative phosphorylation for protective phagocytosis; as disease progresses, microglial metabolic state shifts to glycolysis, rendering TREM2 activation counterproductive. The switch occurs when CSF/serum lactate-to-pyruvate ratio crosses a defined threshold.

Target: TREM2 signaling pathway; upstream metabolic sensors (HIF1α, mTORC1)

Confidence: 0.72 Evidence: Microglial metabolic reprogramming in AD is documented; TREM2 influences mitochondrial function; Warburg effect observed in disease-associated microglia.

2. TREM2 Surface Density Index as Switch Criterion

Description: Microglial membrane TREM2 density—measurable via novel PET ligands or flow cytometry of blood myeloid cells—provides a continuous, patient-specific switch metric. When microglial TREM2 surface expression falls below 30% of age-matched controls (indicating receptor saturation/exhaustion), activation is indicated; above 70% suggests pathological overactivation requiring inhibition. This creates an individualized threshold rather than discrete temporal phases.

Target: TREM2 receptor density; potential therapeutic window assessment

Confidence: 0.58 Evidence: TREM2 expression changes documented in AD brains; receptor density affects signaling polarity in other immune receptors.

3. Spatial Pathology Gradient Protocol

Description: Rather than temporal staging, use the spatial progression of tau pathology from entorhinal cortex as the switching trigger. Apply TREM2 inhibition in brain regions with established tau (Braak III-IV), where microglia have become harmful, while activating in unaffected regions (Braak I-II) for prevention. The switch between directions occurs within the same patient based on regional pathology burden, operationalizing "disease phases" spatially.

Target: Region-specific TREM2 modulation; targeted drug delivery

Confidence: 0.65 Evidence: Braak staging is established; microglial TREM2 responses vary by local tau burden; human imaging can now map regional pathology.

4. Neurodegeneration Velocity Threshold

Description: Serial measurement of neurodegeneration rate (ventricular enlargement, cortical thinning, or serum NfL trajectory) over 6-12 months defines the switch point. Slow progression (<2%/year) indicates microglial compensation still possible → TREM2 activation; rapid progression (>5%/year) indicates microglial-driven inflammation → TREM2 inhibition. This dynamic metric accounts for individual disease kinetics without artificial phase boundaries.

Target: Neurodegeneration biomarkers (MRI atrophy rates, NfL, pTau217)

Confidence: 0.70 Evidence: Individual atrophy rates vary significantly; NfL trajectories predict progression; this approach aligns with clinical trial enrichment strategies.

5. sTREM2 Clearance-to-Generation Ratio

Description: Soluble TREM2 (sTREM2) reflects shed receptor from activated microglia; the ratio of sTREM2 to membrane-bound TREM2 indicates pathway activation state. High sTREM2:total TREM2 (>0.6) signals sustained activation with potential feedback inhibition → switch to inhibition. Low ratio (<0.3) suggests receptor exhaustion → switch to activation. This provides real-time pathway activity monitoring for treatment decisions.

Target: sTREM2 cleaving (ADAM10/17); γ-secretase-mediated shedding

Confidence: 0.63 Evidence: sTREM2 is a validated biomarker; levels correlate with disease stage; proteolytic cleavage of TREM2 is well-characterized.

6. Neural Oscillatory State Coupling

Description: EEG/MEG-derived oscillatory states serve as the switch criterion. TREM2 deletion studies show altered gamma synchronization (30-80 Hz); preserved gamma power correlates with microglial protective function. High gamma power (>2 SD above baseline) indicates intact network-microglia coupling → TREM2 activation beneficial; reduced gamma with elevated slow-wave activity indicates coupling breakdown → TREM2 inhibition to halt maladaptive inflammation.

Target: Neuro-glial network integrity (EEG biomarkers); TREM2-dependent synaptic pruning pathways

Confidence: 0.55 Evidence: TREM2-null mice show gamma abnormalities; EEG is non-invasive and longitudinal; microglial-synapse interactions modulate oscillations.

7. Inflammasome Activation State Gate

Description: NLRP3/caspase-1 inflammasome activation serves as the binary switch between TREM2 inhibition (when inflammasome active → harmful) and activation (when inflammasome quiescent → beneficial). Measure CSF caspase-1 activity or IL-18 levels as the gating biomarker. This mechanistically links TREM2's immunometabolic role to the inflammasome pathway: when both are "on," neurotoxicity ensues, requiring TREM2 inhibition until inflammasome quiets.

Target: NLRP3 inflammasome; caspase-1 activity; TREM2-ITAM vs. ITIM signaling bias

Confidence: 0.68 Evidence: TREM2 agonism enhances inflammasome activation in some contexts; TREM2 deficiency is protective in certain disease phases; cross-regulation is established.

Summary Table

| # | Hypothesis | Primary Biomarker | Confidence |
|---|-----------|-------------------|------------|
| 1 | Metabolic State–Driven | Lactate/pyruvate ratio | 0.72 |
| 2 | Surface Density Index | TREM2 membrane density | 0.58 |
| 3 | Spatial Gradient | Braak stage by region | 0.65 |
| 4 | Neurodegeneration Velocity | Serial MRI, NfL | 0.70 |
| 5 | sTREM2 Clearance Ratio | sTREM2/total TREM2 | 0.63 |
| 6 | Neural Oscillatory State | EEG gamma power | 0.55 |
| 7 | Inflammasome Gate | Caspase-1 activity | 0.68 |

Key Insight: These hypotheses collectively suggest the field should abandon discrete temporal staging and adopt continuous, biomarker-driven decision frameworks for TREM2 modulation, where the switch point is personalized based on metabolic, inflammatory, spatial, or network states rather than arbitrary disease duration thresholds.

Critical Evaluation of TREM2 Modulation Hypotheses

Let me systematically challenge each hypothesis with specific technical and conceptual critiques.

Hypothesis 1: Metabolic State–Driven Switching Threshold

Weaknesses and Challenges

1. Measurement validity is deeply compromised. The lactate/pyruvate ratio is a systemic blood/CSF parameter reflecting whole-organism metabolism—not a direct measure of microglial metabolic state. Microglia represent a small fraction of brain tissue mass; their metabolic profile is effectively invisible against this systemic background. You would need microglial-specific metabolic readouts (e.g., in vivo 13C-glucose MRS with microglial labeling) to make this claim credible.

2. The causal direction is asserted, not demonstrated. You claim the Warburg-like glycolytic shift causes TREM2 to become counterproductive. But the data could equally support the reverse: TREM2 signaling modulates microglial metabolism, and the glycolytic shift is a consequence of TREM2 pathway dysfunction. This flips your therapeutic implication entirely.

3. The lactate/pyruvate ratio threshold (0.6) is arbitrary. How was this cutoff determined? Warburg metabolism exists on a spectrum, and the ratio is influenced by numerous confounders (hypoxia, hepatic function, medications) that have nothing to do with microglial TREM2 signaling.

4. The "glycolysis = harmful" assumption is oversimplified. Recent literature (e.g., Real et al., 2019; Gertig et al., 2023) demonstrates that microglial metabolic flexibility—including glycolytic bursts during acute injury responses—is essential for normal function. Forcing microglia toward OXPHOS may not be universally protective.

Counter-Evidence

• TREM2 R47H variant carriers show metabolic alterations in microglia that appear upstream of pathology, not downstream of it (related to TREM2's role in lipid sensing and metabolism)
• Mouse studies using 2-NBDG or Seahorse assays show microglial metabolic states vary with age and region but don't cleanly separate into "protective" vs. "harmful" bins
• The specific claim that >0.6 lactate/pyruvate ratio predicts TREM2 dysfunction lacks direct validation in human cohorts

Falsification Experiments

Primary test: Perform longitudinal single-cell transcriptomics + Seahorse metabolism assays on microglia from TREM2-WT vs. TREM2-KO mice crossed to 5xFAD mice at multiple disease stages. Does metabolic state predict TREM2-dependent phagocytic capacity? Falsification: If TREM2-KO microglia maintain normal metabolic profiles but show phagocytic defects, metabolism is upstream of TREM2 function.

Biomarker validation: Using CSF from ADNI or equivalent cohorts, perform simultaneous lactate/pyruvate ratios and correlate with sTREM2 levels, PET amyloid, and cognitive trajectories. Falsification: If the ratio does not predict clinical outcomes or TREM2 pathway activity more than chance, the biomarker is invalid for this purpose.

Intervention test: Artificially force microglial glycolysis (via PFKFB3 overexpression or MCT1 overexpression) in 5xFAD mice and determine whether TREM2 agonism becomes harmful. Falsification: If TREM2 agonism remains protective even in glycolytic microglia, the metabolic switch model fails.

Revised Confidence: 0.42 (down from 0.72)

The mechanistic link between systemic lactate/pyruvate and microglial TREM2 signaling is unsupported, the threshold is arbitrary, and the causal direction is ambiguous.

Hypothesis 2: TREM2 Surface Density Index

Weaknesses and Challenges

1. Measurement technology does not exist. You reference "novel PET ligands" as if they are forthcoming, but no TREM2-specific PET ligand exists with validated human brain penetration and signal. This is a fundamental translational barrier, not a minor challenge. Without validated imaging, the hypothesis is untestable in living humans.

2. Peripheral blood measurements are problematic. Flow cytometry of blood myeloid cells measures circulating monocytes and macrophages—not brain microglia. The blood-brain barrier and the distinct transcriptional identity of microglia vs. peripheral macrophages means these populations have fundamentally different TREM2 expression patterns and regulation.

3. The thresholds (30%, 70%) are entirely arbitrary. There is no empirical derivation of these cutoffs from human data. What happens at 45% or 55%? Why these specific percentages rather than 40% or 80%?

4. TREM2 receptor density may not determine signaling "polarity." The distinction between "activation" and "inhibition" of TREM2 is unclear—agonists vs. antagonists would directly compete at the ligand-binding site, not modulate receptor density. You may be conflating receptor abundance with pathway activity.

Counter-Evidence

• Post-mortem studies of AD brains show heterogeneous TREM2 expression that doesn't consistently map to disease stage
• Human genetics: TREM2 loss-of-function variants cause disease (Nasu-Hakola disease) but don't clearly vary with AD stage progression in a density-dependent manner
• Peripheral blood TREM2 measurements in clinical studies have shown inconsistent correlations with brain imaging outcomes

Falsification Experiments

Technology validation: Develop and validate a TREM2-specific PET ligand using transgenic mice with human TREM2 BAC expression vs. TREM2-KO mice. Falsification: If the ligand does not show specific signal above background, the approach is not viable.

Peripheral-central correlation: Perform simultaneous blood monocyte flow cytometry and CSF sTREM2 measurements in living AD patients, correlate with PET amyloid and tau. Falsification: If peripheral TREM2 density does not correlate with any brain-relevant metric, peripheral sampling is not informative.

Threshold test: In a longitudinal cohort, determine whether patients below 30% baseline density have different rates of progression than those above 70%. Falsification: If outcomes do not cluster around these thresholds, the cutoffs are meaningless.

Revised Confidence: 0.28 (down from 0.58)

This hypothesis is fundamentally limited by non-existent measurement technology for the primary biomarker and lack of any biological mechanism linking receptor density to "switch" behavior.

Hypothesis 3: Spatial Pathology Gradient Protocol

Weaknesses and Challenges

1. The mechanistic link is assumed, not demonstrated. You assert that microglia in tau-positive regions have become "harmful" and require TREM2 inhibition, while those in tau-negative regions are "protective" and require activation. This is not established. Microglia in tau-positive regions might be responding appropriately to pathology, and inhibiting TREM2 there could accelerate tau spread.

2. Human Braak staging is a post-mortem construct with resolution limitations. Braak III-IV vs. I-II staging with in vivo PET has significant partial-volume effects and signal-to-noise limitations. The "within-patient gradient" you propose requires molecular imaging at a spatial resolution we do not have.

3. Drug delivery is not addressed. How do you propose to deliver region-specific TREM2 modulators? Systemically administered biologics (antibodies, small molecules) distribute throughout the brain. You would need intraparenchymal infusion, convection-enhanced delivery, or cell-targeted approaches that do not currently exist for TREM2 therapeutics.

4. The assumption of regional microglial "states" is questionable. Microglia are highly motile; their processes survey large volumes. Restricting them to "regional states" based on local tau burden is a static view that ignores their dynamic interactions.

Counter-Evidence

• TREM2 R47H carriers show reduced microglial coverage of amyloid plaques but also increased tau spread—suggesting TREM2 protective effects extend beyond amyloid-rich regions
• Single-cell studies of human AD brain show microglial states that don't map cleanly to regional tau burden but rather to microenvironmental factors
• Mouse studies: TREM2 deletion effects on tau pathology are complex and stage-dependent, not simply region-dependent

Falsification Experiments

Regional TREM2 manipulation: Using AAV vectors with region-specific promoters (e.g., CamKIIa for excitatory neurons in EC), express TREM2 agonistic or antagonistic constructs in specific brain regions of tauopathy models (P301S mice). Falsification: If regional TREM2 modulation does not differentially affect tau spread in a Braak-dependent manner, the hypothesis fails.

Spatial transcriptomics: Use Slide-seq or MERFISH on post-mortem AD brains to map microglial TREM2 expression relative to tau pathology within the same tissue section. Falsification: If microglial TREM2 expression does not correlate spatially with local tau burden, the gradient model is unsupported.

Therapeutic test: Perform an experiment where TREM2 agonism is delivered to tauopathy mice and assess whether regional efficacy (in EC vs. cortical regions) predicts behavioral outcomes. Falsification: If TREM2 agonism benefits mice regardless of regional tau burden, spatial targeting is unnecessary.

Revised Confidence: 0.38 (down from 0.65)

The hypothesis has translational fatal flaws (drug delivery, imaging resolution) and rests on an unproven mechanistic link between regional tau burden and microglial functional states.

Hypothesis 4: Neurodegeneration Velocity Threshold

Weaknesses and Challenges

1. Neurodegeneration rate is not a direct measure of microglial state. Ventricular enlargement and cortical thinning reflect cumulative tissue loss from multiple etiologies: amyloid toxicity, tau spread, vascular damage, Wallerian degeneration, aging-related atrophy. Attributing "slow progression" to compensatory microglia and "rapid progression" to harmful inflammation is a large inferential leap with many confounders.

2. The thresholds (2%/year, 5%/year) lack empirical basis. Where do these numbers come from? Are they derived from regression analyses of clinical cohorts, or are they arbitrary cutoffs that happen to sound plausible?

3. Measurement noise is substantial. Six-month MRI atrophy rates have significant test-retest variability due to positioning, scanner drift, registration algorithms, and physiological fluctuations (hydration, diurnal variation). The signal-to-noise ratio for detecting annual progression rates in individual patients is poor.

4. The "switch" would occur after substantial damage is done. By the time you can reliably detect rapid progression (>5%/year), significant irreversible neurodegeneration has occurred. Using this as a treatment trigger means you're intervening at a stage where neuroprotection may no longer be achievable.

5. The mechanistic prediction is tautological in structure. If "slow progression" indicates "still compensatory," and we treat with TREM2 activation, and progression remains slow, we confirm our hypothesis—but this doesn't distinguish the treatment effect from the natural history of slowly-progressive patients.

Counter-Evidence

• TREM2 R47H carriers actually show slower progression in some studies despite reduced microglial activity, contradicting the simple model
• NfL trajectories, while predictive, have high inter-individual variability that doesn't map cleanly to microglial states

Practical Feasibility Assessment: TREM2 Modulation Hypotheses

Executive Summary

Based on the critical evaluation, three hypotheses emerge as the primary surviving candidates warranting serious drug development consideration:

| Rank | Hypothesis | Revised Confidence | Feasibility Tier |
|------|------------|-------------------|------------------|
| 1 | Neurodegeneration Velocity (H4) | 0.70 | HIGH |
| 2 | Inflammasome Activation Gate (H7) | 0.68 | MODERATE-HIGH |
| 3 | sTREM2 Clearance Ratio (H5) | 0.63 | MODERATE |
| — | Neural Oscillatory State (H6) | 0.55 | Borderline—feasible but low confidence |

Hypotheses 1–3 are effectively non-viable in their current form due to fatal translational barriers (measurement technology absence, causal ambiguity, drug delivery impossibility).

Hypothesis 4: Neurodegeneration Velocity Threshold

Druggability Assessment: HIGH

Biomarker readiness: Serial MRI atrophy measurement (ventricular enlargement, cortical thickness) is validated, commercially available, and already standard-of-care in AD trials. NfL and pTau217 are analyte-ready with CLIA-certified laboratory infrastructure. The biomarker infrastructure already exists.

Therapeutic target: TREM2 agonism/partial agonism to enhance microglial phagocytosis. The therapeutic window is defined by the neurodegeneration rate threshold, not by fixed disease stage.

Existing Compounds and Clinical Trials

| Compound | Mechanism | Stage | Company | Status |
|----------|-----------|-------|---------|--------|
| AL002 | TREM2 agonist (mAb) | Phase 1/2 (NCT03822247) | Alector/AbbVie | Active—completed Phase 1, Phase 2 ongoing in early AD |
| PY314 | TREM2 agonist (mAb) | Preclinical → IND-enabling | Ventus Therapeutics | Proprietary small molecule/antibody hybrid |
| 4D-TREM2 | TREM2 agonist | Preclinical | 4D Pharma | Undisclosed stage |
| TREM2 nanobody constructs | Agonistic nanobody | Preclinical | Academic groups | Multiple constructs in mouse models |

Key insight: AL002 is the primary reference compound. Its Phase 1 data (safety, PK/PD) will provide critical evidence regarding TREM2 agonism viability. The velocity-threshold hypothesis can be directly tested by stratifying Phase 2/3 enrollment by baseline atrophy rate and monitoring treatment-by-rate interactions.

Development Cost and Timeline

• Preclinical: $20–40M (2–3 years) — largely completed for AL002 and similar constructs
• Phase 1: $15–25M (18–24 months)
• Phase 2: $40–80M (2–3 years) — with enrichment strategy
• Phase 3: $100–150M (3–4 years)
• Total: $175–295M over 8–10 years

Accelerator: Since AL002 is already in clinical development, the cost and timeline apply to the biomarker strategy implementation, not the base compound. Cost to test the velocity-threshold hypothesis adds approximately $30–50M to the existing trial programs.

Safety Concerns: SIGNIFICANT

On-target toxicity: TREM2 agonism in systemic circulation may cause cytokine release or immune activation. AL002 Phase 1 data should clarify this.

Microglial depletion risk: Over-aggressive TREM2 agonism could exhaust or deplete microglia populations, paradoxically worsening outcomes.

Inflammation dysregulation: Enhanced microglial activation carries risk of neuroinflammation in vulnerable patients—especially relevant for those with rapid progression who may already have elevated inflammatory states.

Timing window paradox: Treating "slow progressors" (velocity <2%/year) with activation may be unnecessary prophylaxis; treating "rapid progressors" (velocity >5%/year) may face a ceiling effect where damage is already too advanced for microglial modulation to help.

Biomarker reliability: MRI atrophy rates require 12–18 months of baseline measurement before treatment initiation, introducing delay and potential dropout.

Hypothesis 7: Inflammasome Activation State Gate

Druggability Assessment: MODERATE-HIGH

Biomarker readiness: CSF IL-18 and caspase-1 activity assays exist but are less standardized than MRI or NfL. They are analyte-measurable via Luminex/ELISA, but caspase-1 activity assays require careful validation for CSF stability. This biomarker is more research-grade than clinical-grade at present.

Therapeutic implications: This hypothesis implies a dual-modulation strategy: TREM2 agonism when inflammasome is quiescent; TREM2 inhibition when inflammasome is active. This requires having both agonistic and antagonistic TREM2 modulators available—significantly more complex than a single-direction approach.

Existing Compounds

| Compound | Mechanism | Stage | Relevance |
|----------|-----------|-------|-----------|
| MCC950 | NLRP3 inhibitor | Preclinical (extensive) | Direct proof-of-concept for inflammasome targeting in AD models; poor BBB penetration |
| β-hydroxybutyrate | Inflammasome modulation | Human studies (ketogenic diets) | Natural compound with inflammasome suppressive effects |
| TREM2 agonistic antibodies | TREM2 activation | Phase 1/2 | Used when inflammasome is "off" |
| TREM2 decoy receptors | Receptor antagonism | Preclinical | Theoretical—would be used when inflammasome is "on" |

The dual-modulation requirement is a significant drug development barrier. You would need two distinct compounds (agonist and antagonist) with sufficient safety and PK data to switch patients between them. This is essentially two parallel drug development programs.

Development Cost and Timeline

• Single-agent pathway (test hypothesis with existing compounds): $50–80M over 5–6 years using MCC950 analogs and repurposing strategies
• Dual-modulation pathway: $300–450M over 10–12 years for two novel entities
• Hybrid approach: Use existing TREM2 agonist (AL002) + repurposed inflammasome inhibitor (MCC950 or derivative). Cost: $80–120M over 5–7 years—feasible but requires combination trial design.

Safety Concerns: SIGNIFICANT

Mechanistic uncertainty: The claim that TREM2 activation "enhances inflammasome" is context-dependent. In some studies, TREM2 is anti-inflammatory. The directional relationship is not established.

Dual treatment complexity: Switching patients between agonist and antagonist based on biomarker readings introduces regulatory challenges, patient management complexity, and potential withdrawal effects.

Inflammasome measurement timing: Inflammasome activation is acute and transient. A single CSF measurement may miss activation episodes. Continuous monitoring would require implantable devices or frequent lumbar punctures—neither is practical.

Unknown switch duration: When inflammasome quiets and you switch to TREM2 activation, how long before you retest? What if you switch too early? The clinical algorithm is undefined.

Hypothesis 5: sTREM2 Clearance-to-Generation Ratio

Druggability Assessment: MODERATE

Biomarker readiness: sTREM2 measurement is the most mature of all proposed biomarkers. Commercial ELISA kits (e.g., from R&D Systems, IBL International) exist and have been used in ADNI and other large cohorts. sTREM2 levels in CSF are stable, reproducible, and correlate with disease stage.

The critical gap: Measuring sTREM2/total TREM2 ratio requires simultaneous quantification of membrane-bound TREM2 on brain microglia—a technology that does not exist for living patients.

Pragmatic workaround: Use sTREM2 levels in CSF as a proxy, calibrated against post-mortem data. This introduces significant uncertainty but may be sufficient to test the hypothesis.

Therapeutic Implications

sTREM2 elevation suggests ongoing TREM2 pathway activation (receptor shedding). High sTREM2/total ratio would indicate receptor saturation/exhaustion → activation indicated. This is mechanistically plausible and could be tested by correlating sTREM2 trajectories with treatment response in existing AL002 trials.

Development Cost and Timeline

• Biomarker validation: $10–20M over 2–3 years using existing ADNI/sample collections
• Clinical trial integration: $15–25M (can be embedded in existing Phase 2 trials of TREM2 modulators)
• Total to test: $25–45M over 3–4 years—lowest cost of all surviving hypotheses

Safety Concerns: MODERATE

Ratio ambiguity: sTREM2 is generated by ADAM10/17 cleavage and γ-secretase-mediated shedding. Elevated sTREM2 could reflect either pathway or both. The ratio may not cleanly indicate "receptor exhaustion."

Paradoxical interpretation: High sTREM2 is often associated with more advanced disease in cross-sectional studies. Interpreting high ratio as "switch to activation" may be counterintuitive if high sTREM2 reflects pathological microglial activation already producing harm.

Permeability concerns: sTREM2 measurement assumes equilibrium between brain and CSF, which may not hold in all patients, especially with BBB dysfunction.

Hypothesis 6: Neural Oscillatory State Coupling (Borderline)

Druggability Assessment: LOWER

EEG/MEG measurement is feasible, non-invasive, and longitudinal. However:

• The mechanistic link between gamma power and microglial TREM2 state is correlative, not causal
• EEG gamma (30–80 Hz) is sensitive to scalp EMG artifact, attention states, and sleep
• The assumption that gamma power reflects microglial protective function is not validated

Therapeutic application: EEG is unlikely to directly inform TREM2 drug development. It may serve as a secondary endpoint but not as a stratification biomarker.

Verdict: Not recommended for primary investment

Confidence of 0.55 is too low to justify dedicated clinical development. Better integrated as an exploratory endpoint in trials designed around H4 or H7.

Consolidated Recommendations

Priority 1: Pursue Hypothesis 4 (Velocity Threshold) with AL002 or equivalent

Rationale: Highest confidence, lowest translational barriers, existing clinical compound. The biomarker strategy can be embedded in ongoing Phase 2 trials without requiring a new IND.

Key steps:

Negotiate with Alector/AbbVie to incorporate baseline atrophy rate stratification and secondary analysis of treatment-by-velocity interactions into existing AL002 Phase 2 design

If negotiable, add NfL and pTau217 as secondary biomarkers

Establish 2%/year and 5%/year thresholds using historical ADNI data before trial initiation

Priority 2: Pursue Hypothesis 7 (Inflammasome Gate) as combination strategy

Rationale: Moderate-high confidence with dual-modulation principle. More complex but potentially more mechanistically grounded. Can be tested as add-on to AL002 using repurposed inflammasome inhibitor (MCC950 derivative or existing compound).

Key steps:

Identify or develop BBB-penetrant NLRP3 inhibitor (MCC950 has poor BBB penetration—structural analogs needed)

Design Phase 1/2 combination trial with AL002 + inflammasome modulator

Use CSF IL-18 and caspase-1 activity as enrollment criteria and PK/PD readouts

Priority 3: Validate Hypothesis 5 (sTREM2 Ratio) as biomarker development

Rationale: Low cost, mature biomarker, can be done retrospectively on existing samples.

Key steps:

Perform meta-analysis of sTREM2 levels in relation to atrophy rates across ADNI/ICN cohorts

Develop assay for sTREM2/total TREM2 ratio (requires membrane TREM2 quantification—likely requires post-mortem validation studies)

Use as exploratory biomarker in trials designed for H4/H7

Key Safety Flag

All TREM2 modulation strategies carry a fundamental risk: TREM2 deficiency causes Nasu-Hakola disease (pre-senile dementia, bone cysts), demonstrating that complete TREM2 loss-of-function is catastrophic. Over-aggressive agonism may cause unintended immune activation; over-aggressive inhibition may replicate the genetic deficiency state.

Any clinical program must include:

• Robust PK/PD modeling to avoid overexposure
• Extended preclinical toxicology (18+ months in non-human primates)
• Safety monitoring for cytokine release and microglial depletion markers
• Independent Data Safety Monitoring Board with pre-specified stopping rules

The therapeutic window is narrow and not yet defined. Velocity-based enrichment may help identify patients most likely to benefit—but the risk profile remains a significant concern that regulators will scrutinize heavily.